New 'Living Drug' trial offers hope for patients with aggressive blood cancers
NCT ID NCT05705570
Summary
This early-stage trial is testing the safety and best dose of a new type of personalized cell therapy called MB-CART19.1. It is for adults and children (ages 2-70) with certain B-cell blood cancers that have come back or have not responded to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to better target cancer, and then infuse them back into the patient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Israelita Albert Einstein
RECRUITINGSão Paulo, São Paulo, 05652-900, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.